Mason Caren L
Known title: President & CEOCIK: 0001301366
Associated companies
Transaction History
| STAA | ▲ Buy | Option Exercise | 34,928 | $263K | 6/6/2022 | View on chart |
| STAA | ▲ Buy | Option Exercise | 14,765 | $137K | 6/6/2022 | View on chart |
| STAA | ▲ Buy | Option Exercise | 6,191 | $100K | 6/6/2022 | View on chart |
| STAA | ▲ Buy | Option Exercise | 12,886 | $100K | 6/6/2022 | View on chart |
| STAA | ▲ Buy | Option Exercise | 35,000 | $326K | 5/20/2022 | View on chart |
| STAA | ▼ Sell | Open Market | 35,000 | $2.0M | 5/20/2022 | View on chart |
| STAA | ▲ Buy | Option Exercise | 35,000 | $326K | 5/19/2022 | View on chart |
| STAA | ▼ Sell | Open Market | 35,000 | $2.0M | 5/19/2022 | View on chart |
| STAA | ▲ Buy | Option Exercise | 35,000 | $326K | 5/18/2022 | View on chart |
| STAA | ▼ Sell | Open Market | 35,000 | $2.0M | 5/18/2022 | View on chart |
| STAA | ▲ Buy | Option Exercise | 20,269 | $0 | 3/7/2022 | View on chart |
| STAA | ▲ Buy | Option Exercise | 35,000 | $272K | 11/18/2021 | View on chart |
| STAA | ▼ Sell | Open Market | 35,000 | $4.0M | 11/18/2021 | View on chart |
| STAA | ▲ Buy | Option Exercise | 35,000 | $272K | 11/17/2021 | View on chart |
| STAA | ▼ Sell | Open Market | 35,000 | $4.0M | 11/17/2021 | View on chart |
| STAA | ▲ Buy | Option Exercise | 35,000 | $272K | 11/16/2021 | View on chart |
| STAA | ▼ Sell | Open Market | 35,000 | $4.0M | 11/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
STAAR Surgical Names New VP, Faces High Valuation Questions
STAAR Surgical appointed Andrew Pilon as Vice President of Business Development. Recent articles discuss whether the stock is undervalued or risky, noting its high trailing P/E of 283.5. The stock is currently trading near a key support level, with analyst targets ranging from $19.00 to $37.00.
STAAR Surgical Names New VP, Faces High Valuation Questions. STAAR Surgical appointed Andrew Pilon as Vice President of Business Development. Recent articles discuss whether the stock is undervalued or risky, noting its high trailing P/E of 283.5. The stock is currently trading near a key support level, with analyst targets ranging from $19.00 to $37.00.